Tryptamine Salt Forms for CNS Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tryptamine compounds face challenges due to their high potency at serotonin 5-HT2 receptors, leading to adverse events, narrow therapeutic index, and instability in pharmaceutical processing.
Innovation Solution
Development of novel salt forms of N,N-dimethyltryptamine (DMT) and its derivatives with improved physical and pharmaceutical characteristics, such as enhanced stability, bioavailability, and controlled release, for pulmonary administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tryptamine compounds are administered at high doses to achieve therapeutic effects, then receptor activation is improved, but adverse events and toxicity increase
Solution Approach 1:
The patent changes the chemical parameter of tryptamine by converting it to salt forms (e.g., hydrochloride, phosphate, sulfate salts). This parameter change improves solubility and stability, enabling more precise dose control and reducing the variability that leads to adverse events, while maintaining therapeutic efficacy at optimized doses.
Solution Approach 2:
The patent applies local quality by creating deuterated analogs of tryptamine where specific hydrogen atoms are replaced with deuterium at particular positions in the molecular structure. This localized modification enhances metabolic stability and alters pharmacokinetic properties, allowing for improved therapeutic window without proportionally increasing adverse events.
2Object-affected harmful factors
If tryptamine compounds are administered at low doses to reduce adverse events, then safety is improved, but therapeutic efficacy is reduced
Solution Approach 1:
The patent changes the physical-chemical parameters of tryptamine by forming stable salt compounds with controlled solubility characteristics. This enables more predictable absorption and distribution, ensuring that lower doses achieve sufficient therapeutic effect while maintaining a wider safety margin.
Solution Approach 2:
The patent creates composite molecular structures by combining tryptamine with counterions to form salt compounds, and in some cases incorporating deuterium atoms. These composite structures exhibit improved pharmacokinetic properties that enhance therapeutic efficacy at lower doses while reducing toxicity.
3Ease of manufacture
If tryptamine free base is used for pharmaceutical processing, then chemical stability is poor, but synthesis is simpler
Solution Approach 1:
The patent changes the chemical state of tryptamine from free base to salt form, which fundamentally improves stability parameters. The salt forms exhibit enhanced resistance to oxidation, hydrolysis, and degradation, while maintaining compatibility with standard pharmaceutical manufacturing processes.
4Quantity of substance
If tryptamine compounds undergo first-pass metabolism, then oral bioavailability is reduced, but alternative routes are more complex
Solution Approach 1:
The patent changes the solubility parameter of tryptamine through salt formation, which dramatically improves oral bioavailability. The enhanced water solubility of the salt forms facilitates better absorption in the gastrointestinal tract, reducing the impact of first-pass metabolism and eliminating the need for complex alternative administration devices.
Data Source
AI summary
There are disclosed pharmaceutically acceptable salts of tryptamine compounds, the use of such salt forms in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as those adapted for inhalation administration containing the salt forms, methods of delivering the pharmaceutically acceptable salt forms (e.g., via inhalation), and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders, with the salt forms. (Formula (I))